Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neuroscience and Advanced Diagnostic, University of Palermo, 90134 Palermo, Italy.
Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, 70124 Bari, Italy.
Int J Mol Sci. 2021 Mar 5;22(5):2636. doi: 10.3390/ijms22052636.
Coronavirus disease 2019 (COVID-19) is induced by SARS-CoV-2 and may arise as a variety of clinical manifestations, ranging from an asymptomatic condition to a life-threatening disease associated with cytokine storm, multiorgan and respiratory failure. The molecular mechanism behind such variability is still under investigation. Several pieces of experimental evidence suggest that genetic variants influencing the onset, maintenance and resolution of the immune response may be fundamental in predicting the evolution of the disease. The identification of genetic variants behind immune system reactivity and function in COVID-19 may help in the elaboration of personalized therapeutic strategies. In the frenetic look for universally shared treatment plans, those genetic variants that are common to other diseases/models may also help in addressing future research in terms of drug repurposing. In this paper, we discuss the most recent updates about the role of immunogenetics in determining the susceptibility to and the history of SARS-CoV-2 infection. We propose a narrative review of available data, speculating about lessons that we have learnt from other viral infections and immunosenescence, and discussing what kind of aspects of research should be deepened in order to improve our knowledge of how host genetic variability impacts the outcome for COVID-19 patients.
新型冠状病毒病(COVID-19)由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起,可能表现为多种临床症状,从无症状到伴有细胞因子风暴、多器官和呼吸衰竭的危及生命的疾病。这种变异性的分子机制仍在研究中。一些实验证据表明,影响免疫反应起始、维持和缓解的遗传变异可能是预测疾病演变的基础。确定 COVID-19 中免疫系统反应和功能的遗传变异可能有助于制定个性化的治疗策略。在狂热地寻找普遍适用的治疗方案的同时,那些在其他疾病/模型中常见的遗传变异也可能有助于从药物再利用的角度来解决未来的研究问题。本文讨论了免疫遗传学在决定 SARS-CoV-2 易感性和感染史中的最新进展。我们对现有数据进行了叙述性综述,推测我们从其他病毒感染和免疫衰老中吸取的经验教训,并讨论了为了提高我们对宿主遗传变异性如何影响 COVID-19 患者结局的认识,应该深入研究哪些方面。